Phase II Study of Cisplatin plus Cetuximab in Advanced, Recurrent, and Previously Treated Cancers of the Cervix and Evaluation of Epidermal Growth Factor Receptor Immunohistochemical Expression: A Gynecologic Oncology Group Study

BACKGROUND: The purpose of this study was to evaluate the safety and efficacy of cetuximab (C225), an antibody that inhibits epidermal growth factor receptor (EGFR) activity, with cisplatin and to explore associations between EGFR protein expression with patient demographics or clinical outcome. MET...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Farley, John, Sill, Michael W., Birrer, Michael, Walker, Joan, Schilder, Russell J., Thigpen, J. Tate, Coleman, Robert L, Miller, Brigitte E., Rose, Peter G., Lankes, Heather A.
Formato: Artigo
Idioma:Inglês
Publicado: 2011
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC3081894/
https://ncbi.nlm.nih.gov/pubmed/21329967
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ygyno.2011.01.030
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares